Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q1 2021 · 10-Q
Revenue—
Net Income-$2.80M-$2.80MN/M vs Q1 2020 EPS Diluted-$0.03-$0.03N/M vs Q1 2020 Operating Income-$2,037,881N/M Operating Cash Flow-$1,251,500N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
ended Mar 31, 2021 · filed May 24, 2021 · 54 d after period end